Last reviewed · How we verify
Sjogren's Lung Study
Lung involvement in Sjögren's syndrome is common and causes reduced quality of life and increased mortality. Sjögren's syndrome-related lung diseases (SS-RLD) are classified and treated as the primary lung diseases they resemble. Whether this approach is optimal has not been evaluated thoroughly. A critical gap in knowledge is knowing whether SS-RLDs have a unique clinical course and response to therapy. Given the underlying immune system dysfunction in Sjögren's syndrome, the investigators hypothesize that patients with SS-RLD will be more likely to respond to immunosuppressive therapy than patients with the matching primary lung disease. To address this hypothesis, the investigators will prospectively screen for Sjogren's syndrome in patients presenting to pulmonary clinics and compare the clinical course and response to therapy in Sjogren's syndrome positive and negative patients.
Details
| Lead sponsor | Stanford University |
|---|---|
| Status | SUSPENDED |
| Enrolment | 500 |
| Start date | Thu Apr 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Sjogren's Syndrome
- Interstitial Lung Disease
- Primary Pulmonary Lymphoma (Disorder)
- Chronic Bronchiolitis
- Bronchiectasis
- Lung Diseases
- Cystic Lung Disease
- Lymphocytic Interst. Pneumonitis
Countries
United States